Attenuation of IGF-1 antinociceptive action and a reduction in spinal cord gene expression of its receptor in experimental diabetes

Pain

Volumn 75, Issue 1, 1998, Pages 69-74

  Bitar, Milad S ^a   Pilcher, C W T ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Antinociception; Diabetes; IGF 1; IGF 1 mRNA; Spinal cord

Indexed keywords

ATIPAMEZOLE; GENISTEIN; GLIBENCLAMIDE; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; STREPTOZOCIN;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; HYPERGLYCEMIA; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; SPINAL CORD;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; INJECTIONS, SPINAL; INSULIN-LIKE GROWTH FACTOR I; NOCICEPTORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOMEDIN; RNA, MESSENGER; SPINAL CORD;

EID: 0031780473     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(97)00206-6     Document Type: Article

References (41)

1. Ahlgren S.C., Levine J.D. Protein kinase C inhibitors decrease hyperalgesia and C-fiber hyperexcitability in the streptozotocin diabetic rats. J. Neurophysiol. 72:1994;684-692.
2. Anand P. Nerve growth factor regulates nociception in human health and disease. Br. J. Anaesth. 75:1995;201-208.
3. Apfel S.C., Arezzo J.C., Brownlee M., Federoff H., Kessler J.A. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 634:1994;7-12.
4. Becker K., Stegenga S., Conway S. Role of insulin like growth factor 1 in regulating growth hormone release and feedback in male rats. Neuroendocrinology. 61:1995;573-583.
5. Bitar M.S., DeSouza E.B. Diabetes-related changes in brain beta adrenoreceptors in rats as assessed by quantitative autoradiography: relationship to hypothalamic norepinephrine metabolism and pituitary gonadal hormone secretion. J. Pharmacol. Exp. Ther. 254:1990;781-785.
6. 2 adrenoreceptor-mediated nociception in experimental diabetes. Pharmacol. Biochem. Behav. 56:1997;15-20.
7. Bitar M.S., Koulu M., Rapoport S.I., Linnoila M. Diabetes-induced alterations in brain monoamine metabolism in rats. J. Pharmacol. Exp. Ther. 236:1986;432-437.
8. Bitar M.S., Keis A.F., Owusu S.E., Mulven R., DeSouza E.B. Impairment of albuterol-induced suppression of food intake in diabetes mellitus. Pharmacol. Biochem. Behav. 41:1992;483-487.
9. Bitar M.S., Al-Bustan M., Nehme C.L., Pilcher C.W.T. Antinociceptive action of intrathecally administered IGF-1 and the expression of its receptor in rat spinal cord. Brain Res. 737:1996;292-294.
10. Bitar, M.S., Pilcher, C.W.T., Khan, I. and Waldbilling, R.S., Diabetes-induced suppression of IGF-1 and its receptor mRNA levels in the rat superior cervical ganglia, Diabetes Res. Clin. Pract., 1997 (in press).
11. Brewster W.J., Fernyhough P., Diemel L.T., Mohiuddin L., Tomlinson D.R. Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci. 17:1994;321-325.
12. Brown M.J., Asbury A.K. Diabetic Neuropathy, Ann. Neurol. 15:1984;2-12.
13. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
14. Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus, N. Eng. J. Med., 329 (1993) 977-986.
15. Dore S., Kar S., Quirion R. Rediscovering an old friend, IGF-1: potential use in the treatment of neurodegenerative diseases. Trends Neurosci. 20:1997;326-331.
16. Evans E.R., Randell M.S., Bartek J.P.et al. Current perception thresholds in aging. Age Aging. 21:1992;273-279.
17. Feteris W.A. A serum glucose method without protein precipitation. Am. J. Med. Technol. 31:1965;17-21.
18. Greene D.A., Sima A.A.F., Stevens M.J., Feldman E.L., Lattimer S.A. Complications: neuropathy, pathogenetic considerations. Diabetes Care. 15:1992;1902-1925.
19. 2 adrenergic action in diabetic rats. Pharmacol. Biochem. Behav. 39:1991;383-387.
20. Hefti F., Hartikka J., Krusel B. Function of the neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative disease. Neurobiol. Aging. 10:1989;515-533.
21. Hepler J.E., Lund P.K. Molecular biology of the insulin-like growth factors: relevance to nervous system function. Mol. Neurobiol. 2:1990;93-127.
22. Ishii D.N. Implications of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res. Rev. 20:1995;47-67.
23. Ishii D.N., Lupien S.B. Insulin-like growth factors protect against diabetic neuropathy. Effects on sensory nerve regeneration in rats. J. Neurosci. Res. 40:1995;138-144.
24. Janssen P.A.J., Niemegeers C., Dony J. The inhibitory effects of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rats. Arzneittelforschung. 13:1963;502-507.
25. Junod, A., Lambert, A.E., Oric, L., Pictet, R., Gomet, A.S. and Renold, A.E., Studies of the diabetogenic action of streptozotocin, Proc. Soc. Exp. Biol. Med., 126 (1969a) 201-205.
26. Junod, A., Lambert, A.E., Stauffacher, W. and Renold, A.E., Diabetogenic action of streptozotocin: relationship of dose to metabolic response, J. Clin. Invest., 48 (1969b) 2129-2139.
27. Khan I., Collins S.M. Altered expression of sodium pump isoforms in the inflamed intestine of Trichinella spiratis-infected rats. Am. J. Physiol. 264:1993;G1160-G1168.
28. Kiess, W., Kessler, V., Schmitt, S. and Funk, B., Growth hormone and insulin-like growth factor I: basic aspects. In: A. Flyvbjerg, H. Orskov, and K.G.M.M. Alberti (Eds.), Growth Hormone and Insulin-like Growth Factor I in Human and Experimental Diabetes, Wiley, New York, 1993, pp. 1-21.
29. Lackovic Z., Salkovic M., Kuci Z., Relja M. Effect of long lasting diabetes on rat and human brain monoamines. J. Neurochem. 54:1997;143-147.
30. LeRoith D., Werner H., Faria T.N.et al. Insulin-like growth factor receptors: implication for nervous system function. Ann. N.Y. Acad. Sci. 692:1993;22-32.
31. Murphy L.J., Bell G.I., Duckworth M.L., Friesen H.G. Identification, characterization and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-1. Endocrinology. 121:1987;684-691.
32. + channels in the analgesic effect and spinal noradrenaline turnover-enhancing effect of intracerebroventricularly injected morphine in mice. Brain Res. 596:1992;209-214.
33. Roy M., Collier B., Roy A. Hypothalamic-pituitary adrenal axis dysregulation among diabetic and outpatients. Psychiatr. Res. 31:1990;31-37.
34. Takano Y., Yaksh T.L. Characterization of the pharmacology of intrathecally administered alpha-2-agonists and antagonists in rats. J. Pharmacol. Exp. Ther. 261:1992;722-764.
35. Thomas, P.K., Animal models of metabolic neuropathies. In: P.J. Dyck, P.K. Thomas, E.H. Lambert and R. Burge (Eds.), Peripheral Neuropathy, Vol. 1, Saunders, Philadelphia, 1984, pp. 691-706
36. Waldbillig R.J., Heidersbach S., Jones E.B., Schoen T.J., Bitar M.S., Vankuyk E., DeJuan E., Kador P., Chader G.J. Viteral IGF-1 binding proteins are increased in human and animal diabetics: implication for understanding diabetic retinopathy. Curr. Eye Res. 13:1994;539-546.
37. Werner H., Woloschak M., Adama M., Shen-Orr Z., Roberts C.T. Jr., LeRoith D. Developmental regulation of the rat insulin-like growth factor 1 receptor gene. Proc. Natl. Acad. Sci. USA. 86:1989;7451-7455.
38. Wuarin L., Guertin D.M., Ishil D.N. Early reduction in insulin-like growth factor gene expression in diabetic nerve. Exp. Neurol. 130:1994;106-114.
39. Yaksh T. L, Rudy T.A. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17:1976;1031-1036.
40. Zhuang H.-X., Snyder C.K., Pu S.-F., Ishii D.N. Insulin-like growth factors reverse or arrest diabetic neuropathy: effect on hyperalgesia and impaired nerve regeneration in rats. Exp. Neurol. 140:1996;198-205.
41. Zimmerman M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.